Skip to Main Content

Paper Details

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
Clin Cancer Res
149
2021
Author NameAffiliation
Giuseppe CuriglianoIstituto Europeo di Oncologia, IRCCS, University of Milano
Philippe L BedardPrincess Margaret Cancer Centre
  • 1 - 2

Datasets

Release 1.2